Genmab A/S Sponsored ADR $GMAB Shares Sold by Alliancebernstein L.P.

Key Points

• Alliancebernstein L.P. sold 210,066 shares of Genmab A/S, reducing its stake by 1.4% to a total of 14,725,158 shares, valued at approximately $288.3 million.
• Genmab A/S has seen a mixed response from analysts, with ratings ranging from "Strong Buy" to "Hold" and an average price target set at $37.60.
• The company reported a quarterly EPS of $0.54, surpassing estimates, but revenue of $925 million fell short of analyst expectations of $5.77 billion.

Alliancebernstein L.P. lowered its holdings in Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) by 1.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,725,158 shares of the company's stock after selling 210,066 shares during the period. Alliancebernstein L.P. owned approximately 2.30% of Genmab A/S worth $288,319,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the business. Headlands Technologies LLC lifted its holdings in shares of Genmab A/S by 1,525.0% during the 1st quarter. Headlands Technologies LLC now owns 1,560 shares of the company's stock valued at $31,000 after acquiring an additional 1,464 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its stake in shares of Genmab A/S by 124.3% during the first quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company's stock worth $38,000 after purchasing an additional 1,070 shares in the last quarter. Barclays PLC lifted its stake in shares of Genmab A/S by 1,072.8% during the fourth quarter. Barclays PLC now owns 2,498 shares of the company's stock worth $52,000 after purchasing an additional 2,285 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Genmab A/S in the fourth quarter worth about $60,000. Finally, Brooklyn Investment Group grew its stake in shares of Genmab A/S by 729.3% in the first quarter. Brooklyn Investment Group now owns 4,246 shares of the company's stock valued at $83,000 after buying an additional 3,734 shares in the last quarter. Hedge funds and other institutional investors own 7.07% of the company's stock.

Genmab A/S Stock Up 0.9%

Shares of GMAB traded up $0.25 during midday trading on Tuesday, hitting $27.79. The company had a trading volume of 657,452 shares, compared to its average volume of 1,443,279. The stock has a market cap of $17.83 billion, a price-to-earnings ratio of 13.97, a PEG ratio of 1.61 and a beta of 0.93. The company's 50 day moving average price is $22.95 and its 200 day moving average price is $21.49. Genmab A/S Sponsored ADR has a 52 week low of $17.24 and a 52 week high of $27.86.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.54 EPS for the quarter, topping the consensus estimate of $0.39 by $0.15. The business had revenue of $925.00 million for the quarter, compared to analysts' expectations of $5.77 billion. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. Genmab A/S has set its FY 2025 guidance at EPS. Equities analysts anticipate that Genmab A/S Sponsored ADR will post 1.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on GMAB shares. Truist Financial boosted their price target on Genmab A/S from $45.00 to $46.00 and gave the stock a "buy" rating in a research report on Tuesday, July 8th. Wall Street Zen upgraded shares of Genmab A/S from a "hold" rating to a "buy" rating in a research note on Monday, July 28th. Zacks Research lowered shares of Genmab A/S from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 19th. Finally, HC Wainwright boosted their price objective on shares of Genmab A/S from $35.00 to $36.00 and gave the stock a "buy" rating in a report on Friday, August 15th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Genmab A/S currently has a consensus rating of "Moderate Buy" and an average target price of $37.60.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.